Together, these findings indicate that a subset of breast cancer patients with low Smad4 expression might not be susceptible to the known EMT-reversing effects of eribulin, due to upregulation of the EMT-promoting transcription factor Slug. Here, SMAD4 is linked to breast carcinoma.